期刊
BIOCHEMICAL PHARMACOLOGY
卷 85, 期 5, 页码 629-643出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2012.09.018
关键词
Pim kinases; Cancer targets; Therapeutics; PIM inhibitors; Oncogenes
资金
- Foundation for Research in Oncology (FERO)
- Fundacio Josep Botet
- Spanish Ministry of Science and Innovation [SAF2009-08605]
- Consejeria de Ciencia e Innovacion
- Consejeria de Salud of the Junta de Andalucia [CTS-6844, PI-0142]
PIM proteins belong to a family of ser/thr kinases composed of 3 members, PIM1, PIM2 and PIM3, with greatly overlapping functions. PIM kinases are mainly responsible for cell cycle regulation, antiapoptotic activity and the homing and migration of receptor tyrosine kinases mediated via the JAK/STAT pathway. PIM kinases have been found to be upregulated in many hematological malignancies and solid tumors. Although these kinases have been described as weak oncogenes, they are heavily targeted for anticancer drug discovery. The present review summarizes the discoveries made to date regarding PIM kinases as driving oncogenes in the process of tumorigenesis and their validation as drug targets. (C) 2012 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据